Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

Core Insights - Teva Pharmaceutical Industries Ltd. announced long-term improvement in Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over a three-year period in European patients [1][2] - The RIM-TD open-label extension study showed that 65% of patients achieved treatment success as defined by the Clinical Global Impression of Change (CGIC) and 56% by the Patient Global Impression of Change (PGIC) [2] - Deutetrabenazine is already approved in the United States and several other markets, addressing a significant unmet medical need in the treatment of TD [2][4] Industry Context - Tardive Dyskinesia affects approximately 15%-25% of patients on antipsychotic medications, leading to involuntary movements that significantly impair quality of life [2][3] - Current treatment options in Europe are limited and often lack robust clinical evidence, resulting in suboptimal management of the condition [2][3] - The positive outcomes from the RIM-TD study align with previous findings in the overall and U.S. populations, reinforcing the efficacy of deutetrabenazine as a treatment option for TD [2][3]